ONT.L vs PACB
ONT.L: Oxford Nanopore provides portable and scalable DNA and RNA sequencing technology that enables real-time, high-accuracy analysis of genetic material. PACB: Pacific Biosciences provides high-accuracy, long-read genomic sequencing solutions that enable researchers and clinicians to solve complex genetic challenges.
Side-by-side fundamentals
| Metric | ONT.L | PACB | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £1.15 | $1.30 | |
| Market cap as of 2026-08-06 | n/a | $404M | |
| Net margin as of 2026-08-06 | n/a | -80.3% | |
| Gross margin as of 2026-08-06 | n/a | +40.3% | |
| Operating margin as of 2026-08-06 | n/a | -83.3% | |
| ROE as of 2026-08-06 | n/a | -488.4% | |
| ROA as of 2026-08-06 | n/a | -16.1% | |
| Debt / equity as of 2026-08-06 | n/a | 272.23 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +5.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -6.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-08-06 | n/a | 2.32 | |
| 1-year return as of 2026-08-03 close | -42.4% | -8.5% | PACB higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.